Hypersensitivity, Immediate clinical trials

The registry lists 82 studies for Hypersensitivity, Immediate across more than 10 countries. 7 are recruiting or about to start. 32 of them are mainly about Hypersensitivity, Immediate (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23. Counting its 25 narrower conditions too, such as Asthma: 9,055 studies, 1,282 open.

Get an email when these change. Save the Hypersensitivity, Immediate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 64
Recruiting: 5
Withdrawn: 4
Terminated: 3
Status unknown: 3
Not yet recruiting: 2

Phase

Phase 2: 23
Phase 1: 20
Phase 3: 14
Early Phase 1: 1
Phase 4: 1

Where

United States: 41
Canada: 28
France: 8
Germany: 7
Australia: 6
Belgium: 5

Who runs them

Allergy Therapeutics (17) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Ellodi Pharmaceuticals, LP (4) · Assistance Publique - Hôpitaux de Paris (3) · DBV Technologies (3) · Columbia University (2) · AstraZeneca (2) · Merz North America, Inc. (2)

What is being tested here

Drugs under test in Hypersensitivity, Immediate studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Epinephrine	1	0	2
Grass MATA MPL	0	1	4
APT-1011	0	3	3
Benralizumab	0	1	2
Desloratadine	0	2	2
Abrocitinib	0	2	2
KP-001	0	0	1
Tezepelumab	0	0	1
Icatibant	0	0	1
Dupilumab	0	1	1

Drug classes tested here Antihistamines 3

Coming up

0phase 3 studies under way

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Dec 2026Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges · Dr. George Luciuk
Dec 2026Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels · Deniz Göcebe
May 2027Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients · Hikma Pharmaceuticals USA Inc.

Who these studies take

Of the 5 Hypersensitivity, Immediate studies recruiting now, 3 (60%) set no upper age limit and 2 (40%) stop at 75 or younger. 2 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (40%) take healthy volunteers.

Recruiting studies that take each age, of 5
Age	Women	Men
10	0 (0%)	0 (0%)
18	4 (80%)	4 (80%)
30	4 (80%)	4 (80%)
40	4 (80%)	4 (80%)
50	4 (80%)	4 (80%)
65	4 (80%)	4 (80%)
75	3 (60%)	3 (60%)
85	3 (60%)	3 (60%)

Across all 82 studies, recruiting or not: 70% stop at 75 or younger and 60% at 65; 40% take children; 2% are for women only and 0% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 11, 2026.

Newly registered1

Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy PatientsOct 23, 2026NCT07891780

Studies

Recruiting first, then most recently updated. Showing 50 of 82. Browse all 82 → or search them.